Introduction {#s2}
============

Organisms as low as *Caenorhabditis elegans* are colonized with commensal microbiota ([@bib74]), which live in symbiotic relationships with their hosts. Hosts have evolved increasingly complex immune systems to maintain symbiosis with their commensals while responding appropriately to microbial pathogens. Multiple mechanisms exist to enable harmony at the epithelial border, including the presence of a tight epithelial barrier and the secretion of mucus and proteins with direct antimicrobial function. In cases where this defensive barrier fails, microbial pattern recognition receptors can trigger innate defense mechanisms and induce host-protective mechanisms such as fever, diarrhea, and phagocytic cell function. In higher species, an adaptive immune system is capable of providing specific and long-lasting immunity. The orchestration of successful host defense requires effective communication between various cell types, and cytokines are among the messengers employed by the immune system. In this review, we focus on IL-22, a cytokine with multiple roles in host defense and epithelial homeostasis that has recently attracted considerable interest from basic biologists and the pharmaceutical industry alike.

IL-22 is a member of the IL-10 family of cytokines, which also includes IL-19, -20, -24, and -26 and IFNλ, and which has recently been extensively reviewed ([@bib59]; [@bib89]). The IL-22 receptor complex is a unique combination of two subunits, each of which also serves as a receptor for other IL-10 family cytokines: the IL-22RA1 subunit, which can also be used by IL-20 and -24, and the shared IL-10RB subunit, which is also used by IL-10 and -26 and IFNλ. Signaling occurs through Jak1, tyrosine kinase 2 (Tyk2), and STAT3. STAT1, STAT5, protein kinase B (AKT)/mechanistic target of rapamycin (mTOR), and MAPK pathways are also activated by IL-22. While IL-10Rb is broadly expressed in the human body, IL-22 responsiveness is limited by epithelial cell--restricted expression of IL-22RA1 in the lung, gastrointestinal tract, thymus, skin, pancreas, liver, and kidney ([@bib70]). Thus, IL-22 represents a major communication channel between the immune system and specialized tissue cell types.

IL-22 is mainly produced by lymphocytes, such as T helper type 1 (Th1), Th17, Th22, CD8^+^ T cells, γδ T cells, natural killer cells, lymphoid tissue inducer cells, and innate lymphoid type 3 (ILC3) cells ([@bib71]; [Fig. 1](#fig1){ref-type="fig"}). IL-22 production by neutrophils has also been reported ([@bib101]). IL-22 is expressed in response to proinflammatory cytokines secreted by myeloid cells in response to microbial insult, such as IL-1β, IL-6, TNFα, and, chiefly, IL-23 ([@bib69]). In addition, presence and activation of the aryl hydrocarbon receptor is required for efficient IL-22 production ([@bib86]). In murine T helper cells, IL-22 expression is closely tied to expression of RORγT and IL-17, and thus IL-22 is regarded as a Th17 cytokine. However, this linkage is much less evident in the human system, where Th1 and Th22 cells are the dominant sources of IL-22 ([@bib69]).

![**Role of IL-22 in the intestine during homeostasis.** Schematic representation of an epithelial crypt composed of various cell types. Sensing mechanisms that lead to signals that stimulate IL-22 productions are on the left side, and IL-22 effector functions on the different epithelial cell types are on the right side. SAA, serum amyloid A. TA, transit amplifying.](JEM_20192195_Fig1){#fig1}

Role of IL-22 in intestinal stem cells (ISCs) and epithelial regeneration {#s3}
=========================================================================

Intestinal epithelial cells (IECs) are derived from a pool of long-lived, leucine-rich repeat--containing G protein--coupled receptor 5--positive (Lgr5^+^) ISCs. ISCs undergo asymmetric division to self-renew while generating committed transit-amplifying cells, which in turn further differentiate to give rise to all cell types found in the intestinal epithelium ([@bib22]). IL-22RA1 is abundantly expressed across intestinal epithelial lineages ([@bib48]; [@bib102]), and stimulation with IL-22 increases intestinal organoid proliferation and expands organoid size in vitro. IL-22 transgenic mice have an increased number of Ki67^+^ IECs and intestinal crypt cells and show increased crypt height ([@bib102]). Mechanistically, IL-22 and STAT3 signaling promote epithelial cell survival upon radiation or epithelial damage induced by methotrexate ([@bib1]; [@bib48]; [@bib65]), as STAT3 directly induces prosurvival genes, including B cell lymphoma (*BCL*~*xl*~), *MCL1*, and *Hsp70* ([@bib25]; [@bib65]). In line with these observations, IL-22 inhibition or deficiency leads to a reduced frequency of Lgr5^+^ ISCs and defective epithelial regeneration during acute injuries and inflammation ([@bib1]; [@bib94]). It should be noted that the precise target cell type of IL-22 in the intestinal epithelium is a matter of ongoing debate. Two recent papers suggested that the mechanism by which IL-22 promotes regeneration in vivo and organoid growth in vitro involves stimulation of transit-amplifying cells, while it actually suppresses ISC expansion through activation of Wnt and Notch pathways ([@bib96]; [@bib102]). Additional work is required to reconcile these seemingly contradictory findings.

IL-22 is also required for activation of the DNA damage response in the intestinal epithelium. In a series of elegant experiments, [@bib26] demonstrated that selective removal of IL-22RA1 from IECs leads to suppression of apoptosis triggered by DNA damage, and, as a consequence, increased tumor formation in an inflammation-driven tumor model. A group of phytochemicals called glucosinolates, which are abundant in cruciferous vegetables, can give rise to metabolites with DNA-damaging potential yet are also known to activate aryl hydrocarbon receptor signaling, leading to IL-22 production. This evidence thus suggests that this circuit may have evolved to allow for the safe consumption of diets containing DNA-damaging agents.

Mechanisms of IL-22 in intestinal barrier protection {#s4}
====================================================

In mucosal tissues, mucus constitutes the first line of defense against commensal microbes and invading pathogens ([@bib39]). Mucin production by specialized epithelial cells called goblet cells leads to a tightly packed inner mucus layer in the colon, which is impenetrable to commensals under normal conditions ([@bib18]). In the small intestine, mucus is patchier, and contact between commensals and epithelium is possible ([@bib40]). IL-22 directly induces expression of mucin genes in mucosal epithelial cells through STAT3-dependent signaling ([@bib78]). In addition, IL-22 treatment increases the number of goblet cells in the intestinal mucosa, and accordingly, IL-22--deficient animals have reduced goblet cell hyperplasia in response to helminth infection ([@bib84]). Considering that mucins are highly glycosylated proteins, and that glycosylation is mandatory for proper mucin function, it is notable that IL-22 has been shown to promote glycosylation ([@bib24]; [@bib63]). Although it is presently unknown whether IL-22 activity directly impacts glycosylation of mucins, it has been demonstrated that IL-22 can induce intestinal expression of the fucosyltransferase 2 (*FUT2*) gene ([@bib63]), which has been genetically implicated in Crohn's disease ([@bib53]). *FUT2* encodes α1,2-fucosyltransferase, which is expressed constitutively in the stomach and colon and is inducible in the small intestine ([@bib64]). Fucosylation of IECs upon IL-22 stimulation appears to serve a protective role in the gut: it reduces *Helicobacter pylori* attachment to the mucosa ([@bib49]), and Fut2-deficient mice are hypersensitive to infection with *Salmonella typhimurium* ([@bib24]). Bacterial pathogens such as enterohemorrhagic *Escherichia coli* have also been shown to sense fucose and down-regulate virulence factors ([@bib60]). In addition, fucose can also serve as an energy source for some commensal bacteria and thus may shape the microbiome ([@bib64]).

Antimicrobial proteins (AMPs), which include β-defensins, regenerating proteins, and S100 proteins, are a key part of host defense. In the intestine, specialized epithelial cells called Paneth cells, found largely in the small intestine and less frequently in the proximal colon in humans, are the major source of AMPs, and production of AMPs can be elicited by various factors including IL-22 ([@bib6]). In other tissues, IL-22 elicits AMP production in keratinocytes ([@bib45]) and pancreatic acinar cells and stimulates the hepatic acute-phase response ([@bib46]). AMPs are generally defined by their ability to kill or inhibit growth of microbes, and they are integral to the innate immune response in all multicellular organisms, representing a key aspect of barrier protection ([@bib98]).

IL-22 has also been implicated in the pathophysiology of diarrhea, a primitive, physical method of disposing of pathogens and toxins by flushing them out of the body. IL-22 stimulation leads to up-regulation of epithelial claudin-2, a key regulatory subunit of epithelial tight junctions, and can thereby elicit water efflux, diarrhea, and pathogen clearance in the intestine ([@bib83]; [@bib91]). In humans, claudin-2 and IL-22 are both up-regulated in diseases with increased epithelial barrier permeability, such as inflammatory bowel disease (IBD; [@bib93]) and celiac disease ([@bib57]).

Finally, IL-22 also functions in the clearance of pathogens that have already managed to penetrate the barrier. For example, IL-22 can induce IL-18 expression in IECs to facilitate the production of chemokines and cytokines that mediate innate cell recruitment to the site of infection ([@bib55]). Production of hemopexin, a heme scavenging protein that limits iron availability to impair bacterial growth, has recently been shown to be regulated by IL-22 ([@bib72]). IL-22 can also regulate the complement pathway, another ancient host defense mechanism. IL-22 treatment can induce complement C3 gene expression, primarily in the liver but also in the intestine, to induce bacteria killing and control systemic spread of bacteria ([@bib29]). IL-22--inducible production of C3 by the liver is sufficient to protect against pathogens such as pneumococcal pneumonia at distal sites such as the lung ([@bib82]). Thus, IL-22 employs multiple and diverse mechanisms to uphold a strong defensive barrier and provide systemic defense against microbes that manage to cross it.

Role of IL-22 in antimicrobial defense and dysbiosis {#s5}
====================================================

Although IL-22 maintains the intestinal barrier and shapes the microbiome through multiple mechanisms, IL-22 deficiency per se does not result in overt pathological consequences. Subclinically, *IL-22^−/−^* mice do have weakened barrier function and altered microbiota composition, which can be rescued with IL-22 treatment ([@bib76]). IL-23R-deficient animals produce less IL-22 and have increased numbers of segmented filamentous bacteria in the ileum, which generates an environment that is permissive to the development of Th17 cells; this phenotype can be reversed by administration of exogenous IL-22 ([@bib75]). A separate group described IL-22--deficient mice with less bacterial diversity and decreased abundance of *Lactobacillus*, but increased abundance of *Escherichia*, *Salmonella*, and *Helicobacter*, that showed increased susceptibility to dextran sulfate sodium (DSS) colitis in cohoused wild-type animals, indicating that IL-22--deficient animals can harbor microbiota with transferable effects on barrier function ([@bib95]). The defective barrier and increased inflammation in IL-23R knockout and IL-22 knockout mice increase the systemic level of lipopolysaccharide and trimethylamine *N*-oxide, which lead to increased diet-induced atherosclerosis and alcohol-induced hepatitis ([@bib19]).

Beyond its role in intestinal homeostasis, IL-22 plays a role in host defense in response to a variety of infectious agents. ILC3 cell production of IL-22 impedes infection with rotavirus, an enteric pathogen that targets IECs, and loss of ILC3 cells or IL-22 increases viral load ([@bib31]; [@bib97]). Inflammation following influenza viral infection is exacerbated in IL-22--deficient mice ([@bib37]) and reduced in IL-22BP--deficient animals ([@bib30]). Although there is no direct effect on viral load in IL-22--deficient mice in comparison with controls, susceptibility to inflammation and secondary bacterial infection is increased following influenza clearance in the absence of IL-22 ([@bib37]).

*IL-22^−/−^* mice have exacerbated disease in comparison with wild-type controls following *Citrobacter rodentium* infection, which can be partially rescued by treatment with recombinant Reg3γ ([@bib100]). Administration of flagellin resulted in suppression of vancomycin-resistant *Enterococcus* in a TLR5- and IL-22--dependent manner ([@bib42]), and *IL-22^−/−^* mice had slightly increased susceptibility to experimental malaria induced by infection with *Plasmodium chabaudi* ([@bib51]). Furthermore, IL-22 was shown to be critical when mice were infected with *Klebsiella pneumoniae* ([@bib2]) and orally administered *Toxoplasma gondii* ([@bib12]; [@bib56]), the latter of which also caused IL-22--dependent immune pathology ([@bib92]). Infection with *Salmonella enterica serovar Typhimurium* revealed an interesting example of microbial competition and subversion of host defense pathways. *Salmonella* infection resulted in high levels of IL-22 expression, resulting in suppression of commensal Enterobacteriaceae through AMPs. Since *Salmonella* itself is resistant to metal ion starvation and calprotectin, it thus exploited the IL-22 pathway to generate an advantage in the race for colonization ([@bib4]).

Role of IL-22 in metabolism {#s6}
===========================

In addition to shaping microbiota, ILC3 cells also shape metabolism, in part through IL-22--induced suppression of lipid transporter expression ([@bib50]), and in part through systemic effects of IL-22 ([@bib88]). Furthermore, IL-22 can also affect the circadian circuitry in IECs, and mice with IEC-restricted deletion of the circadian transcription factor NFIL3 also display altered metabolism ([@bib90]).

While IL-23 is a major activator of ILC3 cells, there have recently been discoveries of additional important triggers that result in IL-22 production by ILC3s. One group showed that ILC3 cells express the glial cell--derived neurotrophic factor (GDNF) receptor RET. ILC3 cell autonomous *Ret* ablation led to decreased IL-22 production, resulting in dysbiosis and increased susceptibility to bowel inflammation ([@bib36]). Because glial cells express TLRs, they can respond to the presence of bacteria and induce IL-22 production through the release of GDNF family ligands. In another, major, recent development, three independent research groups demonstrated that intestinal ILC3 cells express high levels of genes involved in circadian regulation. Expression of ILC3 genes, including *IL-17* and *IL-22*, is also subject to circadian regulation ([@bib23]; [@bib80]; [@bib87]). While the physiological significance of these observations remains to be fully appreciated, it is already clear that ILC3 autonomous deletion of the circadian clock gene *Arntl* results in altered microbiota composition and increased susceptibility to *C. rodentium* infection ([@bib23]). These data suggest that commensal and environmental signals promote barrier integrity and lipid metabolism through ILC3-mediated production of IL-22.

IL-22 in the pathobiology of human disease {#s7}
==========================================

Alterations in function or loss of epithelial barrier function plays a key role in the pathobiology of diseases of the digestive tract, including IBD and graft-versus-host disease (GVHD), as detailed below. In addition, changes in the balance of epithelial proliferative signals may affect diseases such as colon cancer.

IBD {#s8}
===

Crohn's disease ([@bib3]) and ulcerative colitis ([@bib58]) are the principal types of IBD. Both diseases are characterized by intestinal dysbiosis, compromised barrier function, and a largely overlapping set of genetic risk factors ([@bib41]), yet can differ in localization and histological appearance of intestinal inflammation, risk factors, and comorbidities. IBD results from a dysregulated mucosal immune response in a genetically susceptible individual to commensal bacteria and/or other environmental triggers ([Fig. 2 A](#fig2){ref-type="fig"}). This inflammatory process weakens and destroys the epithelial barrier, resulting in further microbial translocation that can amplify the immune response. Current therapies are limited to antiinflammatory treatments with modest efficacy, and a substantial fraction of active IBD patients fail to respond to these drugs. Therapeutic agents that augment mucosal healing and reinforce the intestinal barrier function may improve therapeutic efficacy in the treatment of IBD.

![**Role of IL-22 in IBD/GVHD and cancer.** **(A and B)** Cell types as in [Fig. 1](#fig1){ref-type="fig"} unless otherwise noted.](JEM_20192195_Fig2){#fig2}

In spite of increased IL-22 levels in patients with IBD ([@bib62]; [@bib73]), barrier dysfunction and disease persist. One possible explanation for the insufficiency of IL-22 to induce adequate healing is concomitant up-regulation of the natural antagonist, IL-22BP ([@bib62]), thus thwarting the potentially protective effect that IL-22 could have. Preclinical data suggest that supraphysiological levels of IL-22 may be required to overcome IL-22BP--mediated inhibition and to induce mucosal healing. Deficiency of IL-22 or IL-22 receptor leads to exacerbated DSS-induced colitis or T cell--induced colitis ([@bib94]). Conversely, IL-22 cytokine or IL-22-Fc fusion protein is efficacious in the DSS-induced mouse model of colitis ([@bib13]; [@bib77]). Treatment with IL-22-Fc in this model also limits permeability for larger molecules such as FITC-dextran, which is used as an experimental surrogate to model bacterial translocation ([@bib66]).

Preclinical IBD models also reveal a potentially more complex role for IL-22 in intestinal inflammation and barrier function. Neutralization of IL-22 improved colitis induced by injection of an antibody directed against CD40 ([@bib17]) or by administration of dinitrobenzene sulfonic acid (DNBS; [@bib67]), suggesting a pathogenic role in these models. In mice ([@bib35]), as well as in humans ([@bib9]), helminth infection has beneficial effects on colitis and is associated with elevated IL-22 production. IL-22 contributes to anti-helminth immunity, as *IL-22^−/−^* mice demonstrated mildly delayed expulsion of the tapeworm *Hymenolepis diminuta*. Intriguingly, however, IL-22 deficiency actually increased the protective effect of *H. diminuta* on DNBS-induced colitis ([@bib67]), which is consistent with a disease-promoting role in DNBS-induced colitis. In another model, macrophage-restricted IL-10Ra deficiency led to severe colitis that was abrogated when *IL-22* was deleted from the germline ([@bib5]). IL-22 may also play different roles based on the location of the inflammation; for example, IL-22 neutralization prevented only colonic, but not cecal, inflammation in *Helicobacter hepaticus*--infected, anti--IL-10R--treated mice ([@bib54]). Finally, neutralization of IL-22 prevented up-regulation of profibrotic genes in trinitrobenzene sulfonic acid--induced colitis, thus implicating IL-22 as a potential mediator of fibrotic complications commonly observed in Crohn's disease ([@bib52]). Collectively, preclinical models of intestinal inflammation suggest that IL-22 effects are strongly dependent on context, complicating predictions of its role in human disease.

As no preclinical model recapitulates all aspects of human IBD, high-quality clinical data will be critical to elucidate the role of IL-22 in human disease. In one approach, an IL-22 IgG4 Fc fusion protein (UTTR1147A) was developed and shown to elicit systemic pharmacodynamic effects when administered to human volunteers ([@bib68]). UTTR1147A is currently being tested in patients with moderate-to-severe ulcerative colitis and Crohn's disease (NCT03558152). Development of gut-restricted IL-22 agonists may be required if the therapeutic index of systemic delivery is not sufficient. Although two IL-22 neutralizing antibodies (ILV-094, also known as fezakinumab, and ILV-095) have also been developed, to our knowledge, they have not been tested in IBD.

GVHD {#s9}
====

GVHD remains the major cause of morbidity and mortality in allogeneic hematopoietic stem cell transplantation ([@bib7]). Before transplantation, patients are conditioned with irradiation or chemotherapy drugs to eliminate host immune cells, which can also lead to epithelial barrier disruption ([@bib33]). The ensuing leakage of microbial products into the systemic circulation is thought to activate recipient antigen presenting cells and augment the subsequent donor T cell expansion, resulting in T cell--dependent inflammation ([Fig. 2 A](#fig2){ref-type="fig"}).

IL-22 regulates GVHD pathogenesis in multiple tissue compartments at different stages. In the intestine, IL-22 from intestinal ILC3 cells supports intestinal epithelial regeneration and barrier function ([@bib28]; [@bib48]). When tested in preclinical models of acute GVHD, treatment with recombinant IL-22 generally improved the disease, increased numbers of Lgr5^+^ stem cells, enhanced expression of antimicrobial peptides Reg3α and Reg3γ, and improved epithelial integrity ([@bib48]; [@bib99]). The beneficial effect of IL-22 is not limited to the intestine, as IL-22 is also critical for the regeneration and survival of thymic epithelial cells ([@bib16]; [@bib61]). IL-22 derived from thymic resident ILC3 supports thymus regeneration during allogeneic transplantation ([@bib15], [@bib16]). Accordingly, lack of recipient IL-22 leads to a reduced number of thymic epithelial cells and subsequent expression of genes related to thymic negative selection (e.g., *Foxn1*, *Aire*). This effect of IL-22 may exacerbate GVHD through defective negative selection of autoreactive T cells ([@bib16]; [@bib61]).

As discussed above, Reg3α and Reg3γ can be secreted by IECs upon IL-22 stimulation ([@bib100]). Elevated serum Reg3α is a prognostic biomarker of severe intestinal GVHD, which occurs in 9--15% of patients receiving allogeneic hematopoietic transplantation ([@bib20]; [@bib99]). Likely, increased serum Reg3α levels reflect a more severely damaged intestinal barrier, which would predispose patients to more severe intestinal GVHD. While IL-22 and Reg3α are elevated in inflamed intestinal tissues, similar to IBD, it is unclear whether they are playing a disease-promoting role, or whether they are part of an insufficient attempt to repair the damage. In the latter case, administration of supraphysiological levels of IL-22 may thus have a protective effect. Such an effect may also be dependent on the timing of the treatment, as intervention before the onset of a strong allogeneic immune response may have a better chance of success. Yet, as in IBD, there are also some preclinical results that tell a cautionary tale. Specifically, one study demonstrated that inflammation, skin epidermal thickness, and fibrosis were all reduced when IL-22 was neutralized in a model of cutaneous GVHD ([@bib21]), assigning a disease-promoting role to IL-22 during chronic inflammation. Such a role would be consistent with other observations of a disease-promoting role of IL-22 in the skin. For example, fezakinumab treatment resulted in improvement of clinical disease scores in patients suffering from atopic dermatitis, primarily in those with elevated levels of serum IL-22 ([@bib10]; [@bib27]). IL-22 levels are also elevated in psoriasis ([@bib11]), but since fezakinumab and ILV-095 were withdrawn early from clinical development in psoriasis (NCT01010542 and NCT00563524, respectively), and no results were published, conclusions on the role of IL-22 in psoriatic skin inflammation cannot be drawn at this time. In light of the disparate findings from murine models, the overall effect of IL-22 agonism in the context of GVHD will have to be determined in the clinic. Currently, an IL-22-IgG2 fusion protein (F-652; [@bib79]) is under investigation for treatment of acute lower-gastrointestinal-tract GHVD (NCT02406551). Separately, this molecule is also being evaluated in patients with alcoholic hepatitis (NCT02655510).

Cancer {#s10}
======

The role of IL-22 in cancer is complex and incompletely understood; data from mouse experiments support both protective and pathogenic functions. The majority of the work to date has been conducted in colorectal cancer and models thereof, although in vitro results and analysis of single nucleotide polymorphisms (SNPs) implicate IL-22 in other forms of cancer ([@bib32]). The incidence of colorectal cancer is increased in patients with IBD and has been associated with ongoing inflammation and genotoxic damage. Barrier function appears to play an important protective role, as intestinal adenomas develop in mice deficient for MUC2, the main intestinal mucin ([@bib85]). Furthermore, as discussed above, epithelial IL-22 responsiveness is required for the elimination of cells with DNA damage and serves an overall protective function in colitis-associated cancer ([@bib26]). As IL-22 generally promotes epithelial homeostasis and suppresses inflammation, it thus may serve a protective role in colorectal cancer models that depend on an inflammatory context.

On the flip side, IL-22 has been shown to promote tumor growth in some models ([@bib14]; [@bib43]). This is consistent with the fact that IL-22 is a potent activator of STAT3 in epithelial cells, and STAT3 is required for the development of colitis-associated cancer ([@bib8]; [@bib25]). Accordingly, *IL-22bp*^−/−^ mice developed significantly more tumors than their wild-type littermates, suggesting that enhanced IL-22 bioactivity in the absence of the endogenous inhibitor can drive tumor formation ([@bib34]). Interestingly, however, *IL-22*^−/−^ mice also developed higher tumor burden. This apparent contradiction was resolved through the use of an IL-22--blocking antibody. When given early, anti--IL-22 administration resulted in higher tumor burden, illustrating a protective role of IL-22 in the context of tumor initiation. When given late, however, anti--IL-22 prevented tumor growth, suggesting that IL-22 can act as a tumor growth factor in established disease ([@bib34]). In line with this hypothesis, HCT116 colorectal cancer cells, representing the late stage of the disease, proliferated and metastasized aggressively in response to IL-22 ([@bib38]). Furthermore, IL-22 expression was twofold higher in human colorectal tumors compared with normal adjacent tissue ([@bib43]). Finally, blockade of IL-22 reduced the growth of human tumor samples upon transfer into immune-deficient mice ([@bib44]).

These findings have implications for the development of IL-22 targeting therapies for human diseases. Indeed, *IL-22* SNPs have been implicated in colorectal cancer ([@bib47]; [@bib81]), although the mechanism of how these SNPs lead to disease is unresolved, and thus a protective or pathogenic role cannot be established. Taken together, a picture emerges in which IL-22 initially acts to suppress tumor initiation, whereas it can potentially promote tumor growth in established disease ([Fig. 2 B](#fig2){ref-type="fig"}).

Summary and outlook {#s11}
===================

IL-22 has emerged as a key regulator of mucosal homeostasis and mediator of host defense in the intestine and elsewhere. It provides a communications channel allowing hematopoietic cells, chiefly lymphocytes, to elicit pleiotropic responses in the epithelium geared toward maintaining a symbiotic relationship with commensal microorganisms while defending the barrier against invasion. In intestinal disease, IL-22 has been demonstrated to promote barrier repair and a return to homeostasis in certain contexts. However, IL-22 has also been shown to promote inflammation and accelerate tumor growth in preclinical models. The consequences of therapeutic modulation of the IL-22 pathway in either direction are currently assessed in patients suffering from various conditions, including IBD, atopic dermatitis, GVHD, and alcohol-induced hepatitis, and will provide additional insight into the role of this cytokine in intestinal disease pathobiology.
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